Myriad Genetics, Inc. MYGN recently announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The ...

Adaptive Biotechnologies. Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer care. New data demonstrates MRD assessed from blood in ...

Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN to co-develop and commercialize minimal residual ...

Minimal residual disease (MRD) testing is becoming a cornerstone of oncology by enabling early detection of cancer recurrence and guiding timely adjustments to therapy from a blood sample.

Myriad Genetics, Inc. (NASDAQ:MYGN) also announced upcoming launches: a commercial Precise MRD test in 2026, an AI-powered Prolaris prostate cancer test with PATHOMIQ, and an expanded MyRisk ...